Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Kezar Life Sciences (KZR) Long-Term Debt Repayments (2025)

Kezar Life Sciences (KZR) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $6.7 million as the latest value for Q4 2025.

For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $6.7 million; the TTM value through Dec 2025 reached $10.6 million, changed N/A, while the annual FY2025 figure was $10.6 million, N/A changed from the prior year.
Long-Term Debt Repayments hit $6.7 million in Q4 2025 for Kezar Life Sciences, up from $1.3 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $6.7 million in Q4 2025 and bottomed at $1.3 million in Q1 2025.